We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 33.02 | 11.86% | 311.41 | 311.40 | 320.00 | 322.54 | 308.68 | 313.42 | 9,644,684 | 05:00:03 |
From May 2019 to May 2024
By Angela Chen
Amgen Inc. said Thursday that a trial of its Vectibix showed positive survival results in patients with a certain type of colorectal cancer.
The phase 3 trial compared the survival benefit of Vectibix, or panitumumab, in a group of patients with chemorefractory wild-type KRAS colorectal cancer. Patients were randomized to receive either Vectibix and best supportive care every two weeks, or best supportive care alone. More patients taking the treatment survived compared to those who had not.
Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women in the U.S., according to the American Cancer Society.
The Food and Drug Administration approved Vectibix in 2006 as a treatment for a different type of colorectal cancer than the one in the most recent study.
Shares of Amgen, up about 0.2% after the close, are roughly flat this year.
Write to Angela Chen at angela.chen@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
